These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 3121202

  • 1. The binding of thio-TEPA in human serum and to isolated serum protein fractions.
    Hagen B, Nilsen OG.
    Cancer Chemother Pharmacol; 1987; 20(4):319-23. PubMed ID: 3121202
    [Abstract] [Full Text] [Related]

  • 2. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.
    Hagen B, Neverdal G, Walstad RA, Nilsen OG.
    Cancer Chemother Pharmacol; 1990; 25(4):257-62. PubMed ID: 1688514
    [Abstract] [Full Text] [Related]

  • 3. Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase.
    Ng SF, Waxman DJ.
    Cancer Res; 1990 Feb 01; 50(3):464-71. PubMed ID: 2105156
    [Abstract] [Full Text] [Related]

  • 4. Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.
    Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG.
    Cancer Chemother Pharmacol; 1987 Feb 01; 19(2):143-8. PubMed ID: 3105905
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.
    Hagen B, Dale O, Neverdal G, Azri S, Nilsen OG.
    Cancer Chemother Pharmacol; 1991 Feb 01; 28(6):441-7. PubMed ID: 1718615
    [Abstract] [Full Text] [Related]

  • 7. On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT).
    Gutierrez PL, Cohen BE, Sosnovsky G, Davis TA, Egorin MJ.
    Cancer Chemother Pharmacol; 1985 Feb 01; 15(3):185-91. PubMed ID: 2996798
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
    van Maanen RJ, van Ooijen RD, Zwikker JW, Huitema AD, Rodenhuis S, Beijnen JH.
    J Chromatogr B Biomed Sci Appl; 1998 Nov 20; 719(1-2):103-12. PubMed ID: 9869370
    [Abstract] [Full Text] [Related]

  • 10. Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study.
    Gutin PH, Weiss HD, Wiernik PH, Walker MD.
    Cancer; 1976 Oct 20; 38(4):1471-5. PubMed ID: 825215
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
    Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH.
    Br J Clin Pharmacol; 2001 Jan 20; 51(1):61-70. PubMed ID: 11167666
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prophylactic effect of triethylenethiophosphoramide on the recurrence rate of superficial bladder tumors.
    Mukamel E, Zitron S, Nissenkorn I, Servadio C.
    Isr J Med Sci; 1980 Jan 20; 16(9-10):714-6. PubMed ID: 6776072
    [Abstract] [Full Text] [Related]

  • 14. Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours.
    Bibby MC, McDermott BJ, Double JA, Phillips RM, Loadman PM, Burgess L.
    Cancer Chemother Pharmacol; 1987 Jan 20; 20(3):203-6. PubMed ID: 2445497
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.
    Hagen B.
    Cancer Chemother Pharmacol; 1991 Jan 20; 27(5):373-8. PubMed ID: 1705489
    [Abstract] [Full Text] [Related]

  • 16. Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.
    van Maanen MJ, Doesburg Smits K, Damen JM, Heck AJ, Beijnen JH.
    Int J Pharm; 2000 May 10; 200(2):187-94. PubMed ID: 10867248
    [Abstract] [Full Text] [Related]

  • 17. Cellular pharmacology of N,N',N''-triethylene thiophosphoramide.
    Miller B, Tenenholz T, Egorin MJ, Sosnovsky G, Rao NU, Gutierrez PL.
    Cancer Lett; 1988 Aug 15; 41(2):157-68. PubMed ID: 3135933
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of thio-TEPA at two different doses.
    Hagen B, Walstad RA, Nilsen OG.
    Cancer Chemother Pharmacol; 1988 Aug 15; 22(4):356-8. PubMed ID: 3139316
    [Abstract] [Full Text] [Related]

  • 19. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
    Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL.
    Cancer Treat Rep; 1986 Jul 15; 70(7):859-64. PubMed ID: 2424593
    [Abstract] [Full Text] [Related]

  • 20. [Serum protein fractions of sarcomatous mice subjected to the combined effect of zymosan and thio-TEPA].
    Bass-Shadkhan KhF, Zakenfel'd GK.
    Klin Lech Zlokach Novoobraz; 1968 Jul 15; 11():215-26. PubMed ID: 4972952
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.